Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its availability have become key issues for patients and healthcare professionals. While tirzepatide has been approved by regulatory agencies, its expensive nature presents a significant barrier to